Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: A CALGB 40503 (Alliance) correlative study.

BACKGROUND: In hormone receptor-positive advanced breast cancer, a progression-free survival benefit was reported with addition of bevacizumab to first-line letrozole. However, increased toxicity was observed. We hypothesized that functional age measures could be used to identify patients at risk fo...

全面介紹

Na minha lista:
書目詳細資料
發表在:Breast Cancer Res Treat
Main Authors: Li, Daneng, McCall, Linda M., Hahn, Olwen M, Hudis, Clifford A., Cohen, Harvey J., Muss, Hyman B., Jatoi, Aminah, Lafky, Jacqueline M., Ballman, Karla V., Winer, Eric P., Tripathy, Debu, Schneider, Bryan, Barry, William, Dickler, Maura N., Hurria, Arti
格式: Artigo
語言:Inglês
出版: 2018
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6076849/
https://ncbi.nlm.nih.gov/pubmed/29789969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-018-4828-5
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍